[The million-level CAR-T anti-cancer drug is included in the basic medical insurance for the first time and the patient’s out-of-pocket payment is reduced to less than 100,000 yuan] "Science and Technology Innovation Board Daily" reported on the 14th that at the 2026 Innovative Drug High-Quality Development Conference held on November 14, the latest versions of the National Medical Insurance Drug Catalog and the Commercial Insurance Innovative Drug Catalog were simultaneously announced. According to the reporter, in the new version of the basic medical insurance catalog, two innovative drugs have been transferred from the previous first version of the commercial insurance innovative drug catalog to the basic medical insurance, reflecting the further deepening of the collaborative connection of the "medical insurance + commercial insurance" dual catalogs. Among them, the million-level CAR-T anti-cancer therapy has made a historic breakthrough. WuXi Junoregi Oronza Injection (trade name: Benoda®) has been included in the basic medical insurance for the first time. After the patient is reimbursed by the medical insurance, the out-of-pocket cost will be reduced to less than 100,000 yuan. This time, "extremely expensive drugs" were able to be included in basic medical insurance at a significant price reduction. The core lies in the localization of key raw materials, which can significantly reduce production costs. (Reporters Xu Hong and Shi Shiyun) (Kechuangban Daily Reporter Xu Hong)